Maw R D
Department of Genitourinary Medicine, Royal Victoria Hospital, Belfast, Northern Ireland, United Kingdom.
Dermatol Clin. 1998 Oct;16(4):829-34, xv. doi: 10.1016/s0733-8635(05)70055-3.
The treatment of anogenital warts has long been unsatisfactory, with high treatment failure rates and relapse rates. It would seem that a good cell-mediated immune response is important for successful treatment, and the development of immune response modifiers such as Imiquimod give hope for an improved outcome for many patients.